指南与共识泌尿男性生殖肿瘤

现代影像学方法促进前列腺癌寡转移定向治疗试验:EORTC影像组共识建议

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.
指南 / 共识 · Lancet Oncol · 2018-10-01

该综述评估了用于识别前列腺癌寡转移的影像学方法,指出指南推荐的标准影像学方法诊断准确性不足,而PET-CT(胆碱或PSMA配体)和全身MRI扩散加权成像可更早、更精确地识别转移。EORTC影像组提出将现代影像学整合到前列腺癌各阶段诊疗路径的临床算法,并建议开展使用现代影像学评估转移定向治疗获益的临床试验。

要点

  • 标准影像学方法诊断寡转移性前列腺癌的准确性不足。
  • PET-CT(胆碱或PSMA配体)和全身MRI扩散加权成像可更早更精确识别转移。
  • EORTC提出将现代影像学整合到前列腺癌各阶段诊疗路径的临床算法。

核心结论

  • 指南推荐的标准影像学方法诊断准确性不足,无法可靠诊断寡转移性前列腺癌。
  • 现代影像学方法(PET-CT用肿瘤特异性放射性示踪剂或全身MRI扩散加权成像)可更早、更精确地识别转移。
  • EORTC影像组建议将现代影像学方法整合到前列腺癌各阶段诊疗路径中以识别寡转移,并提议开展使用现代影像学评估转移定向治疗获益的临床试验。

研究设计与样本

  • 综述类文章,评估用于识别前列腺癌转移的影像学方法,涵盖初次诊断、生化复发或去势抵抗阶段。

主要发现

  • 指南推荐的标准影像学方法诊断准确性不足,无法可靠诊断寡转移性疾病。
  • 使用PET-CT与肿瘤特异性放射性示踪剂(胆碱或前列腺特异性膜抗原配体)以及全身MRI扩散加权成像的现代影像学方法可更早、更精确地识别转移。

临床怎么用

  • EORTC影像组提出临床算法,将现代影像学方法整合到前列腺癌不同阶段的诊疗路径中以识别寡转移性疾病。
  • 建议开展临床试验,使用现代影像学方法评估转移定向治疗的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oligometastatic disease represents a clinical and anatomical manifestation between localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition of oligometastatic disease enables focal, metastasis-directed therapies. These therapies potentially shorten or postpone the use of systemic treatment and can delay further metastatic progression, thus increasing overall survival. Metastasis-directed therapies require imaging methods that definitively recognise oligometastatic disease to validate their efficacy and reliably monitor response, particularly so that morbidity associated with inappropriately treating disease subsequently recognised as polymetastatic can be avoided. In this Review, we assess imaging methods used to identify metastatic prostate cancer at first diagnosis, at biochemical recurrence, or at the castration-resistant stage. Standard imaging methods recommended by guidelines have insufficient diagnostic accuracy for reliably diagnosing oligometastatic disease. Modern imaging methods that use PET-CT with tumour-specific radiotracers (choline or prostate-specific membrane antigen ligand), and increasingly whole-body MRI with diffusion-weighted imaging, allow earlier and more precise identification of metastases. The European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group suggests clinical algorithms to integrate modern imaging methods into the care pathway at the various stages of prostate cancer to identify oligometastatic disease. The EORTC proposes clinical trials that use modern imaging methods to evaluate the benefits of metastasis-directed therapies.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Lecouvet FE, Oprea-Lager DE, Liu Y, et al. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncol. 2018. PMID: 30303127. doi:10.1016/S1470-2045(18)30571-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。